Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
CXCR2 antagonism has been shown to be anti-arthritic, but anti-chemokine therapies usually fail in the clinic owing to redundancy in chemokine-receptor interactions. Here the authors develop single-chain antibodies with multiple chemokine specificities to achieve high affinity and broad specificity...
Guardado en:
Autores principales: | Alessandro Angelini, Yoshishige Miyabe, Daniel Newsted, Byron H. Kwan, Chie Miyabe, Ryan L. Kelly, Misha N. Jamy, Andrew D. Luster, K. Dane Wittrup |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c0b1123a348f40e095ceb7693a617ee1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis
por: Chie Miyabe, et al.
Publicado: (2021) -
CROSSREACTIVE ANTIBODIES AND MEMORY T CELLS TO HUMAN AND ZOONOTIC INFLUENZA A VIRUSES IN VOLUNTEERS
por: I. V. Losev, et al.
Publicado: (2015) -
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
por: Max Meyrath, et al.
Publicado: (2020) -
The major roles of DNA polymerases epsilon and delta at the eukaryotic replication fork are evolutionarily conserved.
por: Izumi Miyabe, et al.
Publicado: (2011) -
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
por: Christos Kontos, et al.
Publicado: (2020)